A trial to assess the amount of insulin antibodies in diabetic patients by surface plasmon resonance

Internal Medicine

Volumn 44, Issue 2, 2005, Pages 100-106

  Kure, Masahiko ^b   Katsura, Yoshiya ^b   Kosano, Hiroshi ^a   Noritake, Masayuki ^b   Watanabe, Toshiya ^b   Iwaki, Yoshiki ^b   Nishigori, Hideo ^a   Matsuoka, Takeshi ^b  

^a TEIKYO UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus; Hypoglycemia; Insulin antibody; Scatchard analysis; Surface plasmon resonance

Indexed keywords

INSULIN; INSULIN ANTIBODY; ISOPHANE INSULIN;

ADULT; AGED; ANTIBODY AFFINITY; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISSOCIATION CONSTANT; DRUG PROTEIN BINDING; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; SCATCHARD PLOT; SURFACE PLASMON RESONANCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DIABETES MELLITUS; FEMALE; HUMANS; INSULIN ANTIBODIES; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SURFACE PLASMON RESONANCE;

EID: 14944339742     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.100     Document Type: Article

References (16)

1. Uchigata Y, Tokunaga K, Nepom G, et al. Differential immunogenetic determinants of polyclonal insulin autoimmune syndrome (Hirata's disease) and monoclonal insulin autoimmune syndrome. Diabetes 44: 1227-1232, 1995.
2. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16 (Suppl 3): 155-165, 1993.
3. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 12: 641-648, 1989.
4. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S. Immunogenicity of recombinant DNA human insulin. Diabetologia 25: 465-469, 1983.
5. 131 metabolism in human subjects: Demonstration of insulin binding globulin in the circulation of insulin-treated subjects. J Clin Invest 35: 170-190, 1956.
6. Berson SA, Yalow RS. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest 38: 1996-2016, 1959.
7. Van Haeften TW, Krom BA, Gerich JE. Prolonged fasting hypoglycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus: effect of insulin withdrawal on insulin-antibody-binding kinetics. Diabetes Care 10: 160-163, 1987.
8. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51: 660-672, 1949.
9. Jonsson U, Fagerstam L, Ivarsson B, et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 11: 620-627, 1991.
10. Karlsson R, Michaelsson A, Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 145: 229-240, 1991.
11. Uchigata Y, Omori Y, Nieda M, Kuwata S, Tokunaga K, Juji T. HLA-DR4 genotype and insulin-processing in insulin autoimmune syndrome. Lancet 340: 1467, 1992.
12. Eguchi Y, Uchigata Y, Yao K, Yokoyama H, Hirata Y, Omori Y. Longitudinal changes of serum insulin concentration and insulin antibody features in persistent insulin autoimmune syndrome (Hirata's disease). Autoimmunity 19: 279-284, 1994.
13. Dixon K, Exon PD, Malins JM. Insulin antibodies and the control of diabetes. Q J Med 176: 543-553, 1975.
14. Kumar D. Insulin antibodies: an analysis of immunoglobulin G subclasses. Diabetes 35: 189A, 1986.
15. Uchigata Y, Kuwata S, Tokunaga K, et al. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet 339: 393-394, 1992.
16. Goldman J, Baldwin D, Pugh W, Rubenstein AH. Equilibrium binding assay and kinetic characterization of insulin antibodies. Diabetes 27: 653-660, 1978.